

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:

Applicants: Finkelman *et al.* : Case No. 91830/625

Serial No. 09/167,088 : Examiner: G. Gabel

Filed: October 6, 1998 : Art Unit: 1641

Title: METHODS FOR MEASURING IN VIVO CYTOKINE PRODUCTION

The Assistant Commissioner of Patents
Washington, DC 20231DECLARATION UNDER 37 CFR 1.132

1. This declaration under 37 CFR Sec. 1.132 is supportive of the Response and Amendment filed herewith.

2. I, Fred Finkelman, M.D., have been employed by the University of Cincinnati since 1995 and that from 1995 to the present time I have been, and still am, engaged in a research program in the field of immunology and particularly cytokine biology;

3. I have reviewed the 13 September 2000 Office Action in the above captioned case and I am familiar with the references, Tamarkin *et al.* (US 5,328,899), Pouletty *et al.* (US 5,612,034), and David *et al.* (US 4,486,530), cited by the Examiner.

4. I disagree with the Examiner's position and maintain that one of ordinary skill in the field of immunology and medical science would not deduce the present invention upon reading the references cited by the Examiner, either alone or in combination.

5. The assay disclosed by Tamarkin reference is a competitive binding assay that measures the ability of an analyte present in a serum sample to block the binding of biotin-labeled analyte to the plate. The assay measures the total of bound and unbound analyte present in a biological fluid. If the analyte is one with a short biological half-life and is not bound by endogenous serum proteins, the Tamarkin assay binding protein would not contact the analyte at all since it would be used up too quickly in the biological system. If endogenous serum proteins bind the analyte, then the methods of the Tamarkin reference would measure some product of the quantity of the analyte and quantity of analyte binding protein produced over an unknown period of time.

Page - 2
09/231,760

Differences in the quantity of analyte measured in two samples might reflect differences in quantity of analyte binding protein in the samples rather than quantity of analyte produced.


6. Tamarkin differs from the claimed process in that it is a competitive binding assay using polyclonal antibodies adhered to a plate to measure the ability of an analyte present in a serum sample to block the binding of biotin-labeled analyte to the plate. The Tamarkin reference teaches using a single, polyclonal antibody, not two specific binding molecules (preferably monoclonal antibodies); it is not utilized *in vivo* to obtain the specific amount of analyte excreted over a fixed period of time; it does not teach using an excess of binding molecule; and it does not teach using a neutralizing binding molecule that binds the analyte to form a targeting moiety:target analyte complex that prevents the analyte's catabolism, excretion, or binding to its respective receptor.

7. Pouletty *et al.* teaches only that one can increase the *in vivo* biological half-life of a compound that normally has a short *in vivo* half-life by injecting it into an animal so that it binds covalently to a molecule that naturally has a long *in vivo* half-life. Pouletty does not suggest that increasing the half-life would provide the results of the present invention by using an excess of a neutralizing binding molecule that prevents catabolism.

8. David *et al.* teaches only that a two-site or sandwich type assay may be used to determine the presence and concentration of an antigen. There is no mention or suggestion that such an assay may be used to determine analyte production *in vivo*.

9. In my opinion, one of ordinary skill in the field of immunology and medical science would find nothing in Tamarkin, Pouletty, or David, alone or in combination that would teach or suggest the present invention or any reason for making it.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Fred Finkelman, M.D.

2/8/01
Date:



UNITED STATES POSTAL SERVICE



UNITED STATES POSTAL SERVICE™

POST OFFICE TO ADDRESSEE

EK652697331US

WWW.USPS.COM

AFFIX POSTAGE OR
CORPORATE ACCOUNT LABEL
ADHIERA AQUÍ EL FRANQUEO O
ETIQUETA DE CUENTA CORPOR.
USO NACIONAL ÚNICAMENTE

ORIGIN (POSTAL USE ONLY)				DELIVERY (POSTAL USE ONLY)			
PG ZIP Code	Day of Delivery	Flat Rate Envelope	Postage	Delivery Attempt	Time	Signature	Signature
04410	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01
04410	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01
04410	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01
04410	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01
04410	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01	10/13/01

CUSTOMER USE ONLY

METHOD OF PAYMENT:

Express Mail Customer Acct. No. X452700 91830/625

Federal Agency Acct. No. or Postal Service Acct. No.

☐ WAIVER OF SIGNATURE (Domestic Only) Additional merchandise insurance is valid if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent if delivery employee judges that article can be left in secure location and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY ☐ Weekend ☐ Holiday

Customer Signature

FROM: (PLEASE PRINT)	PHONE: 513, 651-6800
Frost Brown Todd LLC	
P.O. Box 5715	
Cincinnati, OH 45202	
SA-J/RWoods	91830/625
	96-041
	Finkelman
	2/13/01

TO: (PLEASE PRINT)	PHONE: _____
Assistant Commissioner for Patents	
Box Non-Fee Amendments	
Washington, DC 20231	

PRESS HARD

FOR PICKUP OR TRACKING CALL 1-800-222-1811

WWW.USPS.COM



Label 11-B September 1999

EP-13A SEPTEMBER 1999



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:

Applicants: Finkelman *et al.* : Case No. 91830/625
Serial No. 09/167,088 : Examiner: G. Gabel
Filed: October 6, 1998 : Art Unit: 1641

Title: METHODS FOR MEASURING IN VIVO CYTOKINE PRODUCTION

The Assistant Commissioner of Patents
Washington, DC 20231

DECLARATION UNDER 37 CFR 1.132

1. This declaration under 37 CFR Sec. 1.132 is supportive of the Response and Amendment filed herewith.

2. I, Fred Finkelman, M.D., have been employed by the University of Cincinnati since 1995 and that from 1995 to the present time I have been, and still am, engaged in a research program in the field of immunology and particularly cytokine biology;

3. I have reviewed the 13 September 2000 Office Action in the above captioned case and I am familiar with the references, Tamarkin *et al.* (US 5,328,899), Pouletty *et al.* (US 5,612,034), and David *et al.* (US 4,486,530), cited by the Examiner.

4. I disagree with the Examiner's position and maintain that one of ordinary skill in the field of immunology and medical science would not deduce the present invention upon reading the references cited by the Examiner, either alone or in combination.

5. The assay disclosed by Tamarkin reference is a competitive binding assay that measures the ability of an analyte present in a serum sample to block the binding of biotin-labeled analyte to the plate. The assay measures the total of bound and unbound analyte present in a biological fluid. If the analyte is one with a short biological half-life and is not bound by endogenous serum proteins, the Tamarkin assay binding protein would not contact the analyte at all since it would be used up too quickly in the biological system. If endogenous serum proteins bind the analyte, then the methods of the Tamarkin reference would measure some product of the quantity of the analyte and quantity of analyte binding protein produced over an unknown period of time.

Page - 2
09/231,760

Differences in the quantity of analyte measured in two samples might reflect differences in quantity of analyte binding protein in the samples rather than quantity of analyte produced.

6. Tamarkin differs from the claimed process in that it is a competitive binding assay using polyclonal antibodies adhered to a plate to measure the ability of an analyte present in a serum sample to block the binding of biotin-labeled analyte to the plate. The Tamarkin reference teaches using a single, polyclonal antibody, not two specific binding molecules (preferably monoclonal antibodies); it is not utilized *in vivo* to obtain the specific amount of analyte excreted over a fixed period of time; it does not teach using an excess of binding molecule; and it does not teach using a neutralizing binding molecule that binds the analyte to form a targeting moiety:target analyte complex that prevents the analyte's catabolism, excretion, or binding to its respective receptor.

7. Pouletty *et al.* teaches only that one can increase the *in vivo* biological half-life of a compound that normally has a short *in vivo* half-life by injecting it into an animal so that it binds covalently to a molecule that naturally has a long *in vivo* half-life. Pouletty does not suggest that increasing the half-life would provide the results of the present invention by using an excess of a neutralizing binding molecule that prevents catabolism.

8. David *et al.* teaches only that a two-site or sandwich type assay may be used to determine the presence and concentration of an antigen. There is no mention or suggestion that such an assay may be used to determine analyte production *in vivo*.

9. In my opinion, one of ordinary skill in the field of immunology and medical science would find nothing in Tamarkin, Pouletty, or David, alone or in combination that would teach or suggest the present invention or any reason for making it.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Fred Finkelman, M.D.

Date: